{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:50:16Z","timestamp":1791571816472,"version":"4.3.4"},"reference-count":27,"publisher":"PAGEPress Publications","issue":"2","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Ital Urol Androl"],"abstract":"<jats:p>Introduction and Objective: ExactVuTM is a real-time micro-ultrasound system which provides, according to the Prostate Risk Identification Using Micro-Ultrasound protocol (PRI-MUS), a 300% higher resolution compared to conventional transrectal ultrasound. To evaluate the performance of ExactVuTM in the detection of Clinically significant Prostate Cancer (CsPCa). Materials and methods: Patients with Prostate Cancer diagnosed at fusion biopsy were imaged with ExactVuTM. CsPCa was defined as any Gleason Score \u2265 3+4. ExactVuTM examination was considered as positive when PRI-MUS score was \u2265 3. PRI-MUS scoring system was considered as correct when the fusion biopsy was positive for CsPCa. A transrectal fusion biopsy- proven CsPCa was considered as a gold standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and area under the receiver operator characteristic (ROC) curve (AUC) were calculated. Results: 57 patients out of 68 (84%) had a csPCa. PRI-MUS score was correctly assessed in 68% of cases. Regarding the detection of CsPCa, ExactVuTM \u2019s sensitivity, specificity, PPV, and NPV was 68%, 73%, 93%, and 31%, respectively and the AUC was 0.7 (95% CI 0.5-0-8). For detecting CsPCa in the transition\/ anterior zone the sensitivity, specificity, PPV, and NPV was 45%, 66%, 83% and 25% respectively ant the AUC was 0.5 (95% CI 0.2-0.9). Accounting only the CsPCa located in the peripheral zone, sensitivity, specificity, PPV, and NPV raised up to 74%, 75%, 94%, 33%, respectively with AUC 0.75 (95% CI 0.5-0-9). Conclusions: ExactVuTM provides high resolution of the prostatic peripheral zone and could represent a step forward in the detection of CsPCa as a triage tool. Further studies are needed to confirm these promising results.<\/jats:p>","DOI":"10.4081\/aiua.2021.2.132","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T12:59:33Z","timestamp":1624971573000},"page":"132-138","source":"Crossref","is-referenced-by-count":14,"title":["Diagnostic accuracy of the Novel 29 MHz micro-ultrasound \u201cExactVuTM\u201d for the detection of clinically significant prostate cancer: A prospective single institutional study. A step forward in the diagnosis of prostate cancer"],"prefix":"10.4081","volume":"93","author":[{"given":"Francesco","family":"Chessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelio","family":"Ercolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Gaudiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-1536","authenticated-orcid":false,"given":"Lorenzo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Pultrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Distefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Lodigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Brunocilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"38805","doi-asserted-by":"crossref","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359.","DOI":"10.1002\/ijc.29210"},{"key":"38806","doi-asserted-by":"crossref","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389:815-822.","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"38807","doi-asserted-by":"crossref","unstructured":"D'Agostino D, Mineo Bianchi F, Romagnoli D, et al. MRI\/TRUS FUSION guided biopsy as first approach in ambulatory setting: Feasibility and performance of a new fusion device. Arch Ital Urol Androl. 2020; 91:211-217.","DOI":"10.4081\/aiua.2019.4.211"},{"key":"38808","doi-asserted-by":"crossref","unstructured":"Schiavina R, Borghesi M, Brunocilla E, et al. The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance candidates. Prostate Cancer Prostatic Dis. 2015; 18:270-5.","DOI":"10.1038\/pcan.2015.21"},{"key":"38809","doi-asserted-by":"crossref","unstructured":"D'Agostino D, Mineo Bianchi F, Romagnoli D, et al. Comparison between \"In-bore\" MRI guided prostate biopsy and standard ultrasound guided biopsy in the patient with suspicious prostate cancer: Preliminary results. Arch Ital Urol Androl. 2019; 91:87-92.","DOI":"10.4081\/aiua.2019.2.87"},{"key":"38810","doi-asserted-by":"crossref","unstructured":"Schiavina R, Vagnoni V, D'Agostino D, et al. \"In-bore\" MRI-guided prostate biopsy using an endorectal nonmagnetic device: a prospective study of 70 consecutive patients. Clin Genitourin Cancer. 2017; 15:417-427.","DOI":"10.1016\/j.clgc.2017.01.013"},{"key":"38811","doi-asserted-by":"crossref","unstructured":"Hamoen EHJ, de Rooij M, Witjes JA, et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer detection with multiparametric Magnetic Resonance Imaging: a diagnostic meta-analysis. Eur Urol. 2015; 67:1112-1121.","DOI":"10.1016\/j.eururo.2014.10.033"},{"key":"38812","doi-asserted-by":"crossref","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018; 378:1767-77.","DOI":"10.1056\/NEJMoa1801993"},{"key":"38813","doi-asserted-by":"crossref","unstructured":"Schiavina R, Chessa F, Borghesi M, et al. State-of-the-art imaging techniques in the management of preoperative staging and restaging of prostate cancer. Int J Urol. 2019; 26:18-30.","DOI":"10.1111\/iju.13797"},{"key":"38814","doi-asserted-by":"crossref","unstructured":"Pavlovich CP, Cornish TC; Mullins JK, et al. High-resolution transrectal ultrasound: pilot study of a novel technique for imaging clinically localized prostate cancer Urol Oncol. 2014; 32:34.e27-32.","DOI":"10.1016\/j.urolonc.2013.01.006"},{"key":"38815","doi-asserted-by":"crossref","unstructured":"Halpern EJ, Frauscher F, Strup SE, et al. Prostate: high-frequency Doppler US imaging for cancer detection Radiology. 2002; 225:71-77.","DOI":"10.1148\/radiol.2251011938"},{"key":"38816","doi-asserted-by":"crossref","unstructured":"Ghai S, Eure G, Fradet V. Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. J Urol. 2016; 196:562-9.","DOI":"10.1016\/j.juro.2015.12.093"},{"key":"38817","doi-asserted-by":"crossref","unstructured":"Lughezzani G, Saita A, Lazzeri M, et al. Comparison of the diagnostic accuracy of micro-ultrasound and magnetic resonance imaging\/ultrasound fusion targeted biopsies for the diagnosis of clinically significant prostate cancer. Eur Urol Oncol. 2019; 2:329-332.","DOI":"10.1016\/j.euo.2018.10.001"},{"key":"38818","doi-asserted-by":"crossref","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging\u2014reporting and data system: 2015, version 2. Eur Urol. 2016; 69:16-40.","DOI":"10.1016\/j.eururo.2015.08.052"},{"key":"38819","doi-asserted-by":"crossref","unstructured":"Schiavina R, Bianchi L, Borghesi M, et al. MRI displays the prostatic cancer anatomy and improves the bundles management before robot-assisted radical prostatectomy. J Endourol. 2018; 32:315-321.","DOI":"10.1089\/end.2017.0701"},{"key":"38820","doi-asserted-by":"crossref","unstructured":"Antunes HP, Parada B, Carvalho J, et al. Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. Arch Ital Urol Androl. 2018; 90:191-194.","DOI":"10.4081\/aiua.2018.3.191"},{"key":"38821","doi-asserted-by":"crossref","unstructured":"Barentsz JC, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012 Eur Radiol. 2012; 22:746-757.","DOI":"10.1007\/s00330-011-2377-y"},{"key":"38822","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016; 40:244-52.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"38823","doi-asserted-by":"crossref","unstructured":"Durkan GC, Sheikh N, Johnson P, et al. Improving prostate cancer detection with an extended-core transrectal ultrasonographyguided prostate biopsy protocol. BJU International. 2002; 89:33-39.","DOI":"10.1046\/j.1464-410X.2002.02555.x"},{"key":"38824","doi-asserted-by":"crossref","unstructured":"Porreca A, D'Agostino D, Vigo M, et al. \"In-bore\" MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation. Arch Ital Urol Androl. 2020; 91:224-229.","DOI":"10.4081\/aiua.2019.4.224"},{"key":"38825","unstructured":"Bertaccini A, Consonni P, Schiavina R, et al. Prostate biopsy: approaches Arch Ital Urol Androl. 2005; 77(3 Suppl 1):24-7."},{"key":"38826","unstructured":"Prayer-Galetti T, Ficarra V, Franceschini R. et al. When to carry out prostate biopsy Arch Ital Urol Androl. 2005; 77(3 Suppl 1):3-16."},{"key":"38827","doi-asserted-by":"crossref","unstructured":"Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011; 108:E171-8.","DOI":"10.1111\/j.1464-410X.2011.10112.x"},{"key":"38828","doi-asserted-by":"crossref","unstructured":"Kuru TH, Fu\u0308tterer JJ, Schiffmann J, et al. Transrectal ultrasound (US), contrast-enhanced US, real-time elastography, histoscanning, magnetic resonance imaging (MRI), and MRI-US fusion biopsy in the diagnosis of prostate cancer. Eur Urol Focus. 2015; 1:117-126.","DOI":"10.1016\/j.euf.2015.06.003"},{"key":"38829","doi-asserted-by":"crossref","unstructured":"Taverna G, Morandi G, Seveso M, et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int. 2011; 108:1723-7","DOI":"10.1111\/j.1464-410X.2011.10199.x"},{"key":"38830","doi-asserted-by":"crossref","unstructured":"Ghai S, Van der Kwast T. Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer. Urol Case Rep. 2017; 16:98-100.","DOI":"10.1016\/j.eucr.2017.11.013"},{"key":"38831","doi-asserted-by":"crossref","unstructured":"Schouten MG, van der Leest M, Pokorny M. Why and where do we miss significant prostate cancer with multi-parametric magnetic resonance imaging followed by magnetic resonance-guided and transrectal ultrasound-guided biopsy in biopsy-na\u00efve men? Eur Urol. 2017; 71:896-903","DOI":"10.1016\/j.eururo.2016.12.006"}],"container-title":["Archivio Italiano di Urologia e Andrologia"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2021.2.132\/9407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/download\/aiua.2021.2.132\/9407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T13:00:03Z","timestamp":1624971603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepressjournals.org\/index.php\/aiua\/article\/view\/aiua.2021.2.132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,29]]}},"URL":"https:\/\/doi.org\/10.4081\/aiua.2021.2.132","relation":{},"ISSN":["2282-4197","1124-3562"],"issn-type":[{"value":"2282-4197","type":"electronic"},{"value":"1124-3562","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,28]]}}}